A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs

Makio Imamura, Daisuke Ogawa, Toshikazu Takatori, Maiko Yamaguchi, Tomoyuki Takata, Tomonori Hada, Yoshiaki Ota, Takashi Uehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Specialist oncology pharmacists are being trained in Japan to assist cancer treatment teams. These specialized pharmacists address patients' physical and mental problems in pharmacist-managed cancer care clinics, actively participate in formulating treatment policies, and are beneficial in offering qualitative improvements to patient services and team medical care. However, the effect of outpatient treatment by oncology pharmacists on therapeutic outcomes and medical costs is still unknown. A retroactive comparative analysis of the treatment details and clinical course was conducted among three groups of patients: patients who underwent adjuvant chemotherapy managed by a gynecologic oncologist only (S arm), patients managed by a non-oncologist (general practice gynecologist) only (NS arm), and patients managed by both a nononcologist and a specialist oncology pharmacist (NS+Ph arm). The medical cost per course was significantly lower for patients in the NS+Ph arm than for those in the other two arms. Surprisingly, the outpatient treatment rate in the NS+Ph arm was overwhelmingly high. The involvement of an oncology pharmacist did not make a significant difference in therapeutic outcomes such as recurrence rate and survival. The participation of oncology pharmacists in the management of cancer patients undergoing chemotherapy enables safe outpatient treatment and also reduces medical costs.

Original languageEnglish
Pages (from-to)1956-1962
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number11
Publication statusPublished - Jan 1 2017

Fingerprint

Pharmacists
Retrospective Studies
Costs and Cost Analysis
Outpatients
Therapeutics
Neoplasms
Patient Care Team
Mentally Ill Persons
Managed Care Programs
Adjuvant Chemotherapy
General Practice
Japan
Survival Rate
Recurrence
Drug Therapy

Keywords

  • Cancer chemotherapy
  • Cost
  • Oncology pharmacist
  • Outpatient treatment
  • Pharmacist-managed clinic

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs. / Imamura, Makio; Ogawa, Daisuke; Takatori, Toshikazu; Yamaguchi, Maiko; Takata, Tomoyuki; Hada, Tomonori; Ota, Yoshiaki; Uehara, Takashi.

In: Biological and Pharmaceutical Bulletin, Vol. 40, No. 11, 01.01.2017, p. 1956-1962.

Research output: Contribution to journalArticle

Imamura, M, Ogawa, D, Takatori, T, Yamaguchi, M, Takata, T, Hada, T, Ota, Y & Uehara, T 2017, 'A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs', Biological and Pharmaceutical Bulletin, vol. 40, no. 11, pp. 1956-1962.
Imamura, Makio ; Ogawa, Daisuke ; Takatori, Toshikazu ; Yamaguchi, Maiko ; Takata, Tomoyuki ; Hada, Tomonori ; Ota, Yoshiaki ; Uehara, Takashi. / A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs. In: Biological and Pharmaceutical Bulletin. 2017 ; Vol. 40, No. 11. pp. 1956-1962.
@article{ec271304377b4cc9bbc146ffbb55689f,
title = "A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs",
abstract = "Specialist oncology pharmacists are being trained in Japan to assist cancer treatment teams. These specialized pharmacists address patients' physical and mental problems in pharmacist-managed cancer care clinics, actively participate in formulating treatment policies, and are beneficial in offering qualitative improvements to patient services and team medical care. However, the effect of outpatient treatment by oncology pharmacists on therapeutic outcomes and medical costs is still unknown. A retroactive comparative analysis of the treatment details and clinical course was conducted among three groups of patients: patients who underwent adjuvant chemotherapy managed by a gynecologic oncologist only (S arm), patients managed by a non-oncologist (general practice gynecologist) only (NS arm), and patients managed by both a nononcologist and a specialist oncology pharmacist (NS+Ph arm). The medical cost per course was significantly lower for patients in the NS+Ph arm than for those in the other two arms. Surprisingly, the outpatient treatment rate in the NS+Ph arm was overwhelmingly high. The involvement of an oncology pharmacist did not make a significant difference in therapeutic outcomes such as recurrence rate and survival. The participation of oncology pharmacists in the management of cancer patients undergoing chemotherapy enables safe outpatient treatment and also reduces medical costs.",
keywords = "Cancer chemotherapy, Cost, Oncology pharmacist, Outpatient treatment, Pharmacist-managed clinic",
author = "Makio Imamura and Daisuke Ogawa and Toshikazu Takatori and Maiko Yamaguchi and Tomoyuki Takata and Tomonori Hada and Yoshiaki Ota and Takashi Uehara",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "40",
pages = "1956--1962",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - A retrospective study of the effects of oncology pharmacist participation in treatment on therapeutic outcomes and medical costs

AU - Imamura, Makio

AU - Ogawa, Daisuke

AU - Takatori, Toshikazu

AU - Yamaguchi, Maiko

AU - Takata, Tomoyuki

AU - Hada, Tomonori

AU - Ota, Yoshiaki

AU - Uehara, Takashi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Specialist oncology pharmacists are being trained in Japan to assist cancer treatment teams. These specialized pharmacists address patients' physical and mental problems in pharmacist-managed cancer care clinics, actively participate in formulating treatment policies, and are beneficial in offering qualitative improvements to patient services and team medical care. However, the effect of outpatient treatment by oncology pharmacists on therapeutic outcomes and medical costs is still unknown. A retroactive comparative analysis of the treatment details and clinical course was conducted among three groups of patients: patients who underwent adjuvant chemotherapy managed by a gynecologic oncologist only (S arm), patients managed by a non-oncologist (general practice gynecologist) only (NS arm), and patients managed by both a nononcologist and a specialist oncology pharmacist (NS+Ph arm). The medical cost per course was significantly lower for patients in the NS+Ph arm than for those in the other two arms. Surprisingly, the outpatient treatment rate in the NS+Ph arm was overwhelmingly high. The involvement of an oncology pharmacist did not make a significant difference in therapeutic outcomes such as recurrence rate and survival. The participation of oncology pharmacists in the management of cancer patients undergoing chemotherapy enables safe outpatient treatment and also reduces medical costs.

AB - Specialist oncology pharmacists are being trained in Japan to assist cancer treatment teams. These specialized pharmacists address patients' physical and mental problems in pharmacist-managed cancer care clinics, actively participate in formulating treatment policies, and are beneficial in offering qualitative improvements to patient services and team medical care. However, the effect of outpatient treatment by oncology pharmacists on therapeutic outcomes and medical costs is still unknown. A retroactive comparative analysis of the treatment details and clinical course was conducted among three groups of patients: patients who underwent adjuvant chemotherapy managed by a gynecologic oncologist only (S arm), patients managed by a non-oncologist (general practice gynecologist) only (NS arm), and patients managed by both a nononcologist and a specialist oncology pharmacist (NS+Ph arm). The medical cost per course was significantly lower for patients in the NS+Ph arm than for those in the other two arms. Surprisingly, the outpatient treatment rate in the NS+Ph arm was overwhelmingly high. The involvement of an oncology pharmacist did not make a significant difference in therapeutic outcomes such as recurrence rate and survival. The participation of oncology pharmacists in the management of cancer patients undergoing chemotherapy enables safe outpatient treatment and also reduces medical costs.

KW - Cancer chemotherapy

KW - Cost

KW - Oncology pharmacist

KW - Outpatient treatment

KW - Pharmacist-managed clinic

UR - http://www.scopus.com/inward/record.url?scp=85034027057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034027057&partnerID=8YFLogxK

M3 - Article

C2 - 29093344

AN - SCOPUS:85034027057

VL - 40

SP - 1956

EP - 1962

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 11

ER -